Evotec (EVO) Q1 2026 earnings review
Massive Restructuring Takes Center Stage as Core Business Contracts
Evotec's Q1 2026 results reflect a company in deep transition. Group revenue fell 22% YoY to €156.6M, and Adjusted EBITDA swung to a negative €21.9M. The bottom line was decimated by a €121.9M Net Loss, driven largely by a massive €75M upfront restructuring charge for the 'Project Horizon' initiative. While management points to a difficult comparison against a €25M Sandoz payment in Q1 2025, the underlying business is still contracting—revenues dropped 5.6% even excluding the one-off. The most alarming metric is Just-Evotec Biologics, where gross margin completely collapsed to -24%. With a strategic review now underway by Morgan Stanley and Moelis, Evotec is buying time through severe cost cuts and a timely $100M non-dilutive cash injection from the sale of its Tubulis stake.
🐂 Bull Case
Project Horizon's aggressive restructuring (shrinking to 10 global sites) will remove severe underutilization drag, targeting €75M in structural run-rate savings by 2027.
The expected ~$100M inflow from Gilead's acquisition of Tubulis provides a critical, non-dilutive liquidity bridge while operations are overhauled.
🐻 Bear Case
Just-Evotec Biologics gross margin fell to a disastrous -24%. The business is struggling with the loss of high-margin licensing revenue and underabsorbed production costs.
The macro environment for Discovery & Preclinical Development (D&PD) remains persistently challenging, pushing segment revenues down 15% and destroying operating leverage.
⚖️ Verdict: 🔴
Bearish. The 'measured start' narrative obscures a brutal quarter. A -24% gross margin in a key growth segment and the necessity of a massive restructuring program indicate significant operational distress.
Key Themes
Just-Evotec Biologics Margin Collapse
Reversing. The Just-Evotec Biologics (JEB) segment showed alarming deterioration. While revenue declined 38% due to the missing Sandoz one-off, the real story is profitability: Gross margin imploded from 20.2% in 25Q1 to -23.7% in 26Q1. Management blamed production phasing and temporarily higher material/project costs, but this degree of negative gross margin suggests severe underutilization and pricing pressure.
Base Business Contradicts 'Measured Start' Narrative
Decelerating. Management described the quarter as a 'measured start' and heavily emphasized the €25M Sandoz comparison gap. However, calculating the base business reveals underlying weakness: Excluding Sandoz, revenues still declined by 5.6% (from €176.9M to €166.9M). This contradicts the positive narrative and proves the core portfolio is still contracting.
Project Horizon Forces Necessary Pain
Accelerating. Evotec is finally addressing its bloated cost structure. The company booked a massive €75M reorganization provision in Q1 (mostly severance and €14.9M in PP&E impairments) to shrink its global footprint to 10 sites. This is expected to generate ~€75M in run-rate savings by 2027 (20-30% materializing this year), directly addressing the underutilization crushing the D&PD segment.
Non-Dilutive Cash Injections De-Risk Balance Sheet
Stable. The timing of Gilead's acquisition of Tubulis is a massive win for Evotec. The ~$100M upfront cash payment (plus up to $58M in milestones) for Evotec's minority equity stake provides a vital liquidity buffer, ensuring the company can fund the €100M total cash costs of Project Horizon without needing to tap unfavorable debt or equity markets.
Macro Pressures on Early-Stage Discovery Continue
Stable weakness. Management explicitly cited a 'persistently challenging market environment' for the D&PD segment, where revenues dropped 15% to €119.8M. The biotech funding winter is still suppressing demand for early-stage outsourced CRO work, forcing Evotec to rely heavily on its larger strategic partnerships to weather the drought.
AI-Enabled Scientific Validation
Stable. Despite financial turmoil, scientific execution remains intact. Evotec and Almirall successfully nominated a preclinical development candidate for inflammatory skin diseases in just two years using Evotec's AI/ML platforms. Furthermore, the Gates Foundation awarded a ~$1.7M grant for AI-driven optimization of monoclonal antibodies, validating Evotec's specific technological edge in shortening discovery timelines.
Executive Overhaul and Strategic Review
Reversing. The C-suite is being radically restructured simultaneously with the operational footprint. A new CFO (Claire Hinshelwood) and COO (Dr. Ingrid Müller) are taking over. Concurrently, Morgan Stanley and Moelis have been retained for a comprehensive strategic review. This level of simultaneous transition introduces immense execution risk.
Other KPIs
Despite the severe net loss, operating cash outflow improved significantly from €(31.8)M in 25Q1, driven by favorable working capital changes. Total liquidity remains solid at €444.8M.
Decelerating. R&D spend was slashed by 32.5% YoY (from €14.9M). Management states this reflects tight control over investments, but it also highlights the harsh necessity to preserve cash over internal pipeline advancement.
Guidance
Management expects Q2-Q4 to recover significantly to hit this target. Achieving the €740M midpoint implies flat-to-slight growth over a normalized FY25, relying heavily on a projected H2 CRO recovery and 40% growth in non-Sandoz JEB activities.
With Q1 already at €(21.9)M, the company must generate roughly €42M in Adjusted EBITDA over the next three quarters just to hit the low end of guidance. This requires an aggressive, near-immediate margin turnaround driven by Project Horizon savings.
Maintained. Evotec still projects an 8-12% CAGR leading up to 2030. However, with current gross margins dipping negative, the path to a 20% Adjusted EBITDA margin looks increasingly steep and entirely dependent on flawless execution of the Horizon restructuring.
Key Questions
Biologics Margin Recovery
With Just-Evotec Biologics posting a -24% gross margin this quarter, what is the exact timeline and capacity utilization threshold required for this segment to return to breakeven?
D&PD Market Normalization
Guidance relies on the CRO business recovering to low single-digit growth in H2 2026. What specific leading indicators in the RFP or bookings pipeline provide confidence that the biotech funding winter is actually thawing for early-stage discovery?
Horizon Execution Risk
You are shrinking the global footprint to 10 sites while simultaneously swapping out the CFO and COO. How is management ensuring that project handoffs and customer relationships aren't disrupted during this massive internal reorganization?